Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008;3(1):1-19.

Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases

Malgorzata Smola  1 , Thierry Vandamme, Adam Sokolowski
Affiliations
Review

Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases

Malgorzata Smola et al. Int J Nanomedicine. 2008.

Abstract

The purpose of this review is to discuss the impact of nanocarriers administered by pulmonary route to treat and to diagnose respiratory and non respiratory diseases. Indeed, during the past 10 years, the removal of chlorofluorocarbon propellants from industrial and household products intended for the pulmonary route has lead to the developments of new alternative products. Amongst these ones, on one hand, a lot of attention has been focused to improve the bioavailability of marketed drugs intended for respiratory diseases and to develop new concepts for pulmonary administration of drugs and, on the other hand, to use the pulmonary route to administer drugs for systemic diseases. This has led to some marketed products through the last decade. Although the introduction of nanotechnology permitted to step over numerous problems and to improve the bioavailability of drugs, there are, however, unresolved delivery problems to be still addressed. These scientific and industrial innovations and challenges are discussed along this review together with an analysis of the current situation concerning the industrial developments.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Regions of the respiratory system.
See this image and copyright information in PMC

References

    1. Abu-Dahab R, Schäfer UF, Lehr C-M. Lectin-functionalized liposomes for pulmonary drug delivery: effect of nebulization on stability and bioadhesion. Eur J Pharm Sci. 2001;14:37–46. - PubMed
    1. Adjei LA, Gupta PK. Inhalation delivery of therapeutic peptides and proteins. In: Lenfant C, editor. Lung biology in health and disease. New York: Marcel Dekker, Inc; 1997. pp. 1–913.
    1. Armstrong DJ, Elliott PNC, Ford JL, et al. Poly – (D,L – lactic acid) microspheres incorporating histological dyes for intra-pulmonary histopathological investigations. J Pharm Pharmacol. 1996;48:258–62. - PubMed
    1. Arppe J, Vidgren M, Waldrep JC. Pulmonary pharmacokinetics of cyclosporin A liposomes. Int J Pharm. 1998;161:205–14.
    1. Benameur H, Latour N, Schandene L, et al. Liposome-incorporated dexamethasone palmitate inhibits in-vitro lymphocyte response to mitogen. J Pharm Pharmacol. 1995;47:812–17. - PubMed